Edwards Lifesciences Corporation (EWL.F)
| Previous close | 81.55 |
| Open | 82.20 |
| Bid | 82.04 x 11700 |
| Ask | 82.86 x 11600 |
| Day's range | 82.20 - 82.20 |
| 52-week range | 57.10 - 88.92 |
| Volume | |
| Avg. volume | 139 |
| Market cap | 50.154B |
| Beta (5Y monthly) | 1.10 |
| PE ratio (TTM) | 38.41 |
| EPS (TTM) | 2.14 |
| Earnings date | 24 Jul 2024 - 29 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 119.36 |
Simply Wall St.A fantastic week for Edwards Lifesciences Corporation's (NYSE:EW) 84% institutional owners, one-year returns continue to impress
Key Insights Given the large stake in the stock by institutions, Edwards Lifesciences' stock price might be vulnerable...
BenzingaIndian Rival Meril Accuses Edwards Lifesciences Of Anti-Competitive Behavior In EU Antitrust Complaint
On Monday, U.S. heart valve manufacturer Edwards Lifesciences Corporation (NYSE:EW) faced an EU antitrust complaint from Indian competitor Meril, alleging anti-competitive behavior, particularly concerning patents. This could potentially intensify EU regulators’ scrutiny of Edwards, Reuters reports. Recent regulatory actions in the United States and Europe aim to promote fair competition and maintain drug and product affordability, especially for smaller innovative companies challenging larger i
- Reuters
Edwards Lifesciences hit with Meril's EU antitrust complaint
U.S. heart valve maker Edwards Lifesciences has been hit with an EU antitrust complaint by Indian rival Meril including for allegedly anti-competitive practices related to patents, a move that could bolster EU regulators' scrutiny of Edwards. Meril has filed a complaint with the European Commission, the company told Reuters. The two companies have for years sparred over heart valve patents in various courts around the world.
